TAXOTERE W/ CONTINUOUS INFUSION TOPOTECAN IN ADVANCED MALIGNANCIES

泰索帝和拓扑替康是相对较新的药物，已被证明具有抗癌活性。这两种药物都会毒害并最终不可逆转地破坏某些类型的癌细胞。本研究的目的是确定患者是否可以安全地同时给予这两种药物。虽然我们将观察肿瘤的缩小，但这项研究的主要重点是确定这些药物是否可以有效地联合使用。患者将被分配到一个手臂和剂量水平，这将决定药物的量和接受药物的顺序。第一次治疗将在医院进行大约4天。额外的治疗，如果耐受良好，将作为门诊给予。他索替通过静脉注射一小时以上。托培替康将连续给予超过72小时。21天后重复治疗。如果治疗耐受性良好，患者最多可接受六种治疗。如果T&T治疗因任何原因停止，我们将对这些患者进行另一个月的随访，以评估延迟副作用的可能性。

Taxotere and Topotecan are relatively new drugs that have proven anti-cancer activity. Both agents poison and ultimately irreversibly damage some types of cancer cells. The purpose of this research is to determine in patients whether the two agents can be given safely together. While we will be watching for decreasing size of the tumor, the primary focus of this study is to determine if these agents can be given together effectively. Patients will be assigned to an arm and dose level which will determine the amount of drug and the order of receiving the agents. The first treatment will be given in the hospital over approximately 4 days. Additional treatments, if well tolerated, will be given as an outpatient. Taxotere is given through a vein over an hour. Topetecan will be given continuously over 72 hours. The treatment will be repeated in 21 days. If the treatment is well tolerated, patients may receive a maximum of six treatments. If T&T treatment is discontinued for any reason, we will follow these patients for another month to assess possbility of delayed side effects.